Background
==========

Gastric cancer remains the most common cause of cancer-related deaths worldwide, with poor patient prognosis and a lack of adequate treatment methods. Although surgical resection is the primary treatment method for gastric cancer, more extensive surgery is accompanied by greater risks of surgery-related morbidity and mortality \[[@B1]\]. The mortality rate for patients undergoing gastrectomy surgery in western countries often exceeds 5%, and may be as high as 16% \[[@B2]\], although the rate in Japanese patients has been reported as being less than 2% \[[@B3]\]. Moreover, the efficacy of concomitant splenectomy remains unclear. As our understanding of the role of the spleen in the immunological defenses of the body and in the prevention of sepsis has increased, the value of routine removal of the spleen, *en bloc* with the stomach, during the course of radical, potentially curative resection for gastric cancer has been reassessed.

In this study, we retrospectively analyzed long-term survival data of patients who underwent gastrectomy, with or without splenectomy, for gastric cancer at a single institution. We found that operative complication rates were significantly higher in patients undergoing concomitant splenectomy, and it carried no benefit to patients already undergoing gastrectomy. Consequently, we believe, its routine use in radical resection for gastric cancer should be abandoned.

Methods
=======

Patients
--------

We identified 214 patients with histologically confirmed gastric cancer who had undergone radical surgery at the First Affiliated Hospital of China Medical University between 1980 and 2003, Patients were included in the study if they: 1) had histologically confirmed gastric cancer; 2) had undergone curative surgery; 3) had a complete medical record available; and 4) had never received neoadjuvant therapies. The number of patients at every period of diagnosis and the number treated by each surgeon were roughly equal.

All patients were followed up by mail or telephone interviews, and the final follow-up was in December 2008. Clinical, surgical, and pathological findings at the time of surgery and at each follow-up were collected and recorded in the database.

Ethics approval
---------------

The study protocol was approved by the Ethics Committee of China Medical University. \[The patients signed the informed consent about operation and so on routinly, we don't need another consent about this study any more\].

Surgical procedures and classifications of gastric cancer
---------------------------------------------------------

All operations were performed at the First Affiliated Hospital of China Medical University. Surgical procedures and pathological assessments were standardized in accordance with the Japanese classification of gastric cancer \[[@B4]\]. All patients underwent standard total or distal sub-total gastrectomy, depending on the location and macroscopic appearance of the primary tumor.

Endpoints and follow-up
-----------------------

The primary endpoint was 5-year overall survival (OS) rate. OS was calculated from the date of surgery until the date of death or final follow-up contact. Patients remaining alive at the date of final follow-up were censored at that point. Patients were followed up every 6 months for the first 5 years after surgery, and every 12 months thereafter.

Statistical analyses
--------------------

OS was analyzed in all eligible patients. Survival curves were determined by the Kaplan--Meier method, and compared by the log-rank test. Potential prognostic factors were entered into a Cox regression model. For univariate analyses, prognostic factors of interest and treatment group were deemed covariates in the Cox regression model. Subgroups were analyzed in this model to evaluate interactions between treatment and subgroup. All *P*-values were two-sided, with *P* \< 0.05 considered significant. All statistical analyses were performed using SPSS software (version 16.0; SPSS Inc., Chicago, IL, USA).

Results
=======

Of the 214 patients who underwent gastrectomy for gastric cancer from 1980 to 2003, 100 patients (median age 59 years) underwent gastrectomy plus splenectomy (G + S), while the remaining 114 (median age 55.5 years), underwent gastrectomy alone (G-A). All patients were followed up for at least 5 years, until December 19, 2008.

The baseline demographic and clinical characteristics of the two groups were similar (Table  [1](#T1){ref-type="table"}). Of the 214 patients, 13 (6.1%) had early gastric cancer (EGC) confined to the submucosa or mucosa. All patients underwent curative resection. Total gastrectomy was performed in 60 of the 100 (60%) patients who underwent G + S, and in 68 of the 114 (60%) who underwent G-A. Complications were more common (*P* = 0.005) in the G + S group than in the gastrectomy-alone group (Table  [1](#T1){ref-type="table"}; Table  [2](#T2){ref-type="table"}). A total of 26 patients, 12% in each group, received adjuvant chemotherapy after surgery.The median follow-up durations were 18 months in the G + S group and 26.5 months in the G-A group. By the end of follow-up, 87 of the 100 patients (87%) who underwent G + S and 83 of the 114 (73%) who underwent G-A had died. Kaplan-Meier analysis of OS in these two groups showed a significant between-group difference (Figure  [1](#F1){ref-type="fig"}). The 5-year OS rates were 33.8% (95% CI 24.2 to 43.4%) in the G-A group and 28.8% (95% CI 19.6 to 38.0%) in the G + S group (p = 0.013 by the log-rank test).

###### 

**Characteristics of patients undergoing gastrectomy with and without splenectomy (n = 214)**^**a**^

  **Characteristic**          **G + S (n = 100)**   **G-A (n = 114)**   ***P*-value**
  -------------------------- --------------------- ------------------- ---------------
  Age, years                                                                0.836
    ≤ 55                            32 (32)              38 (33)       
    \> 55                           68 (68)              76 (67)       
  Sex                                                                       0.190
   Men                              82 (82)              85 (75)       
   Women                            18 (18)              29 (25)       
  Tumor size, cm                                                            0.393
    ≤ 4                             23 (23)              27 (24)       
   5 to 6                           26 (26)              21 (18)       
    \> 6                            51 (51)              66 (58)       
  Pathological tumor stage                                                  0.600
   T1                                5 (9)                8 (9)        
   T2                               28 (49)              45 (53)       
   T3                               16 (28)              26 (31)       
   T4                               8 (14)                6 (7)        
  Pathological nodal stage                                                  0.153
   N0                               10 (15)              24 (28)       
   N1                               20 (31)              29 (34)       
   N2                               23 (35)              23 (27)       
   N3                               12 (19)              9 (11)        
  TNM stage                                                                 0.355
   IA                                2 (2)                5 (4)        
   IB                               19 (19)              23 (20)       
   II                               18 (18)              30 (26)       
   IIIA                             29 (29)              31 (27)       
   IIIB                             14 (14)              14 (12)       
   IV                               18 (18)              11 (10)       
  Gross type (Borrman)                                                      0.154
   I                                 3 (3)                2 (2)        
   II                               20 (20)              12 (11)       
   III                              59 (60)              66 (61)       
   IV                               17 (17)              29 (27)       
  Type of gastrectomy                                                       0.958
   Total                            60 (60)              68 (60)       
   Sub-total                        40 (40)              46 (40)       
  Complications                     24 (24)              11 (10)          0.005^c^
  Adjunctive therapy                12 (12)              14 (12)            0.903

*Abbreviations*: *G + S* gastrectomy plus splenectomy, *G-A* gastrectomy alone, *TMN* tumor, node, metastasis.

^a^Data are given as n (%).

^c^Significant.

###### 

**Complications in patients undergoing gastrectomy with and without splenectomy (n = 214)**^**a**^

  **Complications**         **G + S (n = 100)**   **GA (n = 114)**
  ------------------------ --------------------- ------------------
  Intestinal obstruction           1 (1)               3 (3)
  Pneumonia                        1 (1)               1 (1)
  Abdominal abscess                7 (7)               2 (2)
  Anastomotic leakage              7 (7)               0 (0)
  Other                            8 (8)               5 (4)

*Abbreviations*: *G + S* gastrectomy plus splenectomy, *G-A* gastrectomy alone.

^a^Data are given as n (%).

![**Kaplan-Meier analysis of overall survival (OS) in patients undergoing gastrectomy plus splenectomy and those undergoing gastrectomy alone.** The 5-year OS rates in these two groups were 28.8% (95% CI 19.6 to 38.0%) and 33.8% (95% CI 24.2 to 43.4%), respectively (*P* = 0.013 by the log-rank test).](1477-7819-12-193-1){#F1}

The hazard ratio (HR) for death was 1.456 (95% CI 1.076 to 1.970; *P* = 0.015) in the G + S relative to the G-A group (Table  [3](#T3){ref-type="table"}). After adjustment for nine baseline variables (age, sex, tumor size, Borrmann type, T stage, lymph-node stage, TNM stage, complications and type of gastrectomy) using Cox regression analysis, the HR was 1.777 (95% CI 1.137 to 2.777; *P* = 0.012) (Table  [3](#T3){ref-type="table"}). As expected, multivariate analysis showed that Borrmann type IV and advanced TNM stages were significantly associated with poor survival (Table  [3](#T3){ref-type="table"}).

###### 

HR for death in the intention-to-treat population (n = 214)

                             **Univariate analyses**    **Multivariate analyses**                              
  -------------------------- -------------------------- --------------------------- -------------------------- ----------
  Age, years                                            0.251                                                  0.242
    ≤ 55                     1 (Ref)                                                1 (Ref)                     
    \> 55                    1.212 (0.872 to 1.685)     0.251                       1.427 (0.823 to 2.476)     0.242
  Sex                                                   0.444                                                  0.473
   Women                     1 (Ref)                                                1 (Ref)                     
   Men                       0.867 (0.600 to 1.251)     0.444                       0.756 (0.430 to 1.328)     0.473
  Tumor size, cm                                        0.000                                                  0.172
    ≤ 4                      1 (Ref)                                                1 (Ref)                     
   5 to 6                    1.492 (0.932 to 2.390)     0.096                       1.562 (0.763 to 3.199)     0.222
    \> 6                     2.058 (1.368 to 3.097)     0.001                       1.808 (0.928 to 3.522)     0.082
  Pathological tumor stage                              0.000                                                  0.698
   T1                        1 (Ref)                                                1 (Ref)                     
   T2                        4.134 (2.968 to 5.756)     0.000                       1.484 (0.828 to 2.658)     0.184
   T3                        6.508 (4.643 to 9.121)     0.000                       1.120 (0.409 to 3.066)     0.826
   T4                        9.231 (5.752 to 14.813)    0.000                       1.763 (0.149 to 3.906)     0.745
  Pathological nodal stage                              0.000                                                  0.413
   N0                        1 (Ref)                                                1 (Ref)                     
   N1                        2.253 (1.912 to 2.654)     0.000                       1.201 (0.764 to 1.888)     0.426
   N2                        4.128 (3.390 to 5.027)     0.000                       1.348 (0.586 to 3.100)     0.482
   N3                        8.215 (6.301 to 10.711)    0.000                       1.722 (0.515 to 5.756)     0.377
  TNM stage                                             0.000                                                  0.016^c^
   IA                        1 (Ref)                                                1 (Ref)                     
   IB                        2.402 (1.611 to 3.580)     0.000                       2.778 (1.504 to 5.132)     0.001^c^
   II                        4.589 (3.148 to 6.690)     0.000                       5.461 (2.049 to 14.559)    0.001^c^
   IIIA                      8.334 (5.708 to 12.168)    0.000                       10.403 (2.567 to 42.162)   0.001^c^
   IIIB                      11.148 (7.406 to 16.782)   0.000                       13.570 (2.182 to 84.410)   0.005^c^
   IV                        18.123 (9.654 to 28.184)   0.000                       27.360 (3.028 to 47.256)   0.003^c^
  Gross type (Borrmann)                                 0.001                                                  0.034^c^
   I                         1 (Ref)                    0.984                       1 (Ref)                     
   II                        0.989 (0.343 to 2.853)                                 3.316 (0.727 to 15.120)    0.122
   III                       1.337 (0.491 to 3.645)     0.570                       3.358 (0.894 to 12.611)    0.073
   IV                        2.561 (1.909 to 7.210)     0.025                       4.584 (1.201 to 17.499)    0.026^c^
  Type of gastrectomy                                   0.463                                                  0.297
   Total                     1 (Ref)                                                1 (Ref)                     
   Sub-total                 0.891 (0.654 to 1.213)     0.463                       1.139 (0.722 to 1.796)     0.297
  Operation                                             0.015                                                  0.012^c^
   Without splenectomy       1 (Ref)                                                1 (Ref)                     
   With splenectomy          1.456 (1.076 to 1.970)     0.015                       1.777 (1.137 to 2.777)     0.012^c^
  Complications                                         0.887                                                  0.173
   No                        1 (Ref)                                                1 (Ref)                     
   Yes                       0.992 (0.894 to 1.101)     0.887                       0.502 (0.254 to 1.193)     0.173

*Abbreviations*: *HR* hazard ratio, *Ref* reference category.

^a^Derived from tests of HR for prognostic factors in univariate model adjusted for type of surgery in a Cox proportional-hazards model.

^b^Cox-regression analysis, controlling for the prognostic factors listed in the table.

^c^Significant.

G-A was significantly more beneficial than G + S in men, and in patients with tumor size \>6 cm, Borrmann type III tumors, or those who underwent subt-otal gastrectomy (Table  [4](#T4){ref-type="table"}). We therefore would not recommend routine splenectomy in patients with gastric cancer who require sub-total gastrectomy, unless the tumor lies close to or directly invades the splenic hilum. Our results indicate that splenectomy should not be included in the treatment of patients with curable gastric cancer.

###### 

Tests for heterogeneity of treatment effect according to the clinicopathological characteristics of the patients undergoing gastrectomy with and without splenectomy

  **Subgroup**               **G + S, patients/total patients, n**   **G-A, patients/total patients, n**   **HR (95% CI)**^**a**^    ***P*-value**^**b**^
  -------------------------- --------------------------------------- ------------------------------------- ------------------------- ----------------------
  Deaths                     87/100                                  83/114                                1.456 (1.076 to 1.970)     
  Age, years                                                                                                                          
    ≤ 55                     26/32                                   25/38                                 1.559 (0.897 to 2.709)    0.116
    \> 55                    61/68                                   58/76                                 1.377 (0.960 to 1.974)    0.082
  Sex                                                                                                                                 
   Women                     17/18                                   20/29                                 1.527 (0.797 to 2.926)    0.201
   Men                       70/82                                   63/85                                 1.433 (1.018 to 2.018)    0.039^c^
  Tumor size, cm                                                                                                                      
    ≤ 4                      16/23                                   15/27                                 1.606 (0.778 to 3.314)    0.200
   5 to 6                    23/26                                   18/21                                 1.135 (0.604 to 2.134)    0.694
    \> 6                     48/51                                   50/66                                 1.606 (1.079 to 2.391)    0.019^c^
  Pathological tumor stage                                                                                                            
   T1                        5/5                                     7/8                                   3.458 (0.790 to 15.144)   0.100
   T2                        21/28                                   30/45                                 1.478 (0.840 to 2.598)    0.175
   T3                        14/16                                   19/26                                 0.871 (0.426 to 1.781)    0.706
   T4                        7/8                                     4/6                                   1.803 (0.521 to 6.238)    0.352
  Pathological nodal stage                                                                                                            
   N0                        7/10                                    15/24                                 1.800 (0.707 to 4.586)    0.218
   N1                        16/20                                   19/29                                 1.373 (0.704 to 2.678)    0.353
   N2                        21/23                                   19/23                                 1.221 (0.648 to 2.300)    0.537
   N3                        11/12                                   7/9                                   0.969 (0.345 to 2.722)    0.952
  TNM stage                                                                                                                           
   IA                        2/2                                     5/5                                   2.783 (0.386 to 20.066)   0.310
   IB                        16/19                                   14/23                                 1.433 (0.694 to 2.961)    0.331
   II                        15/18                                   21/30                                 1.875 (0.955 to 3.681)    0.068
   IIIA                      23/29                                   22/31                                 1.027 (0.567 to 1.860)    0.930
   IIIB                      13/14                                   13/14                                 0.800 (0.359 to 1.783)    0.585
   IV                        18/18                                   8/11                                  1.649 (0.706 to 3.850)    0.248
  Gross type (Borrmann)                                                                                                               
   I                         2/3                                     2/2                                   1.405 (0.125 to 15.838)   0.783
   II                        18/20                                   7/12                                  1.908 (0.790 to 4.609)    0.151
   III                       50/59                                   46/66                                 1.536 (1.028 to 2.296)    0.036^c^
   IV                        16/17                                   23/29                                 1.623 (0.847 to 3.111)    0.145
  Type of gastrectomy                                                                                                                 
   Total                     53/60                                   50/68                                 1.317 (0.893 to 1.942)    0.165
   Sub-total                 34/40                                   33/46                                 1.700 (1.032 to 2.803)    0.037^c^

*Abbreviations*: *G + S* gastrectomy plus splenectomy, *G-A* gastrectomy alone, *HR* hazard ratio, *TNM* tumor, node, metastasis.

^a^HR \>1 indicates that G-A was superior, whereas HR \<1 indicates that G + S was superior.

^b^The *P*-values are for HRs for deaths in each group (G + S or GA), with 95% CI.

^c^Considered significantly better for G + S.

Discussion
==========

The spleen is an organ that protects the host against infection and perhaps also against tumor micrometastases, and knowledge about its immunological functions has increased markedly in recent years. Although lymph nodes in the hiluma of the spleen may be affected by gastric tumors, the spleen itself is seldom affected. Our retrospective comparison showed that OS was significantly higher and complication rates significantly lower in patients undergoing G-A than in those undergoing G + S for curative resection of gastric cancer.

More extended surgery is associated with increased risks of operative morbidity and mortality. We found that removal of the spleen during the course of resection for gastric carcinoma significantly increased operative morbidity rates compared with spleen preservation (24% versus 10%, *P* \< 0.05). The increased morbidity after splenectomy may due to the higher incidence of infectious complications after gastrectomy. Mortality rates in western countries for patients undergoing gastrectomy often exceed 5% and may be as high as 16% \[[@B2]\]. Thus, G + S should not be considered the standard curative surgical procedure in patients with gastric cancer unless the addition of splenectomy is found to significantly benefit patients by reducing operative morbidity and mortality rates or improving long-term survival. In the current study, no evidence was found that removal of the spleen led to any increase in 5-year OS rate after potentially curative resection. We found that the 5-year OS rates were 28.8% in patients undergoing G + S and 33.8% in patients undergoing G-A, similar to previous findings \[[@B4]-[@B7]\]. Splenectomy was also shown to negatively influence survival, and in addition, increased length of hospital stay and probability of death \[[@B8]-[@B10]\].

In addition to the extent of the surgery, the operative skill and experience of the surgeon(s) and the workload of cases are also important factors for survival rates \[[@B11],[@B12]\]. Many studies have reported a relationship between the number of cases treated in a hospital and the outcomes of cancer treatment \[[@B12]-[@B17]\]. Moreover, the uniformity of treatment is also important. Our study was carried out in a hospital that performs a high volume of dissections for gastric cancer, with low morbidity and mortality rates. All participating surgeons were from the same department, which minimizes the variation in individual operating skill and management, and balances the comparisons between the two groups without bias from the skill of individual surgeons.

Because G-A is associated with lower mortality and adequate PS when performed in selected institutions with sufficient surgical experience and good postoperative management, we recommend that most patients with curable gastric cancer should undergo total or sub-total gastrectomy combined with radical lymphadenectomy, a type of surgery compatible with the preservation of the spleen.

Conclusions
===========

Splenectomy does not benefit patients undergoing radical resections for gastric cancer, and should not be performed.
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